Group 1 - The core point of the article is that Xintian Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its Xinlikang capsules, aimed at treating cancer-related fatigue [1] - As of October 14, Xintian Pharmaceutical's market capitalization is 2.6 billion yuan [2] - For the first half of 2025, Xintian Pharmaceutical's revenue composition shows that main business revenue accounts for 99.9%, while other business revenue accounts for 0.1% [1]

Core Viewpoint - The company Xin Tian Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its Xin Likang capsules, aimed at treating cancer-related fatigue [1] Group 1 - The company has announced the receipt of a clinical trial approval notice for Xin Likang capsules [1] - The clinical trial is specifically for the treatment of cancer-related fatigue [1]

Core Viewpoint - The company Xin Tian Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its Xin Likang capsules, aimed at treating cancer-related fatigue [1] Group 1 - The approval allows the company to conduct clinical trials for Xin Likang capsules [1] - The indication for the clinical trial is specifically for the treatment of cancer-related fatigue [1]

Core Viewpoint - The company Xin Tian Pharmaceutical has received approval from the National Medical Products Administration to conduct clinical trials for its Xin Likang capsules, aimed at treating cancer-related fatigue, marking a significant step in addressing an unmet medical need in this area [1] Company Summary - Xin Tian Pharmaceutical announced the receipt of a clinical trial approval notice for Xin Likang capsules, which are a unique Miao medicine [1] - The clinical trials will focus on validating the efficacy of Xin Likang capsules in treating cancer-related fatigue specifically in colon cancer patients [1] - Currently, there are no drugs available in the domestic or international markets for the treatment of cancer-related fatigue [1] Industry Summary - The approval for clinical trials highlights a potential breakthrough in the pharmaceutical industry, particularly in the niche of cancer-related fatigue treatment [1] - The development of Xin Likang capsules could fill a significant gap in the market, as there are no existing therapies for this condition [1] - The progress and results of the clinical trials remain uncertain, and the company will fulfill its information disclosure obligations as required [1]

证券代码：002873 证券简称：新天药业 公告编号：2025-055 贵阳新天药业股份有限公司 关于获得欣力康胶囊《药物临床试验批准通知书》的 公告 剂型：胶囊剂 申请事项：临床试验 受理号：CXZL2500054 通知书编号：2025LP02676 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年7月24日受理的欣力康胶囊（CXZL2500054）临床试验申请符合药品注册的有 关要求，在进一步完善临床试验方案的基础上，同意本品开展用于癌因性疲乏的 临床试验。 二、药品研发及相关情况 欣力康胶囊为公司的独家苗药品种，胶囊制剂，规格0.45g/粒。是公司自主 研发的中药。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 贵阳新天药业股份有限公司（以下简称"公司"）于近日收到了国家药品监 督管理局下发的欣力康胶囊《药品临床试验批准通知书》，同意欣力康胶囊开展 "用于癌因性疲乏的治疗"的临床试验，现将相关情况公告如下： 一、药物临床试验批准通知书的主要内容 产品名称：欣力康胶囊 产品功能主治：苗医：布苯怡象，维象样丢象，泱窇沓痂；中医：补 ...

（编辑 袁冠琳） 证券日报网讯 新天药业9月30日在互动平台回答投资者提问时表示，公司已于2024年7月26日披露了终 止发行股份购买资产事项的公告，具体内容详见公司已发布的相关公告。但打造行业领先的综合性医药 企业仍是公司的长期发展战略。 ...

证券日报网讯新天药业（002873）9月29日在互动平台回答投资者提问时表示，公司持续增加对汇伦医 药的投资是基于公司中长期发展规划目标所做出的审慎决策。汇伦医药作为一家聚焦于重大疾病和危重 症治疗领域的创新型医药企业，具备较强的小分子化药创新研发能力。通过增加对汇伦医药的投资，加 大公司在小分子化药领域的投入，有利于进一步提升公司未来的市场竞争力，加速打造公司实现行业领 先的综合性医药企业战略目标。 ...

证券代码：002873 证券简称：新天药业 公告编号：2025-054 贵阳新天药业股份有限公司 关于对参股公司增资并受让其部分股权暨关联交易 的进展公告 一、对参股公司增资并受让其部分股权暨关联交易概述 贵阳新天药业股份有限公司（以下简称"公司"）于2025年8月21日召开了第 八届董事会第二次会议，审议通过了《关于对参股公司增资并受让其部分股权暨 关联交易的议案》，同意公司使用自有资金4,000万元以"增资+受让"方式，增 加对参股公司上海汇伦医药股份有限公司（以下简称"汇伦医药"）的股权投资， 其中：以2,000万元对汇伦医药进行增资，增资对应可获得汇伦医药股份235.2941 万股；以2,000万元受让湖北苹湖创业投资有限公司（以下简称"苹湖创投"） 持有的汇伦医药股份235.2941万股（以下将增资事项及受让汇伦医药部分股权合 称为"本次交易"）。同时参与汇伦医药本次增资的还有新增股东烟台天自汇莱 创业投资基金合伙企业（有限合伙）增资3,700万元，新增股东北京金慧丰投资 管理有限公司增资1,500万元，各主体本次增资合计7,200万元，增资价格均为人 民币8.5元/股。参与汇伦医药本次增资的各投资 ...

Company Overview - Xintian Pharmaceutical Co., Ltd. is located in Guizhou Province, established on August 11, 1995, and listed on May 19, 2017. The company specializes in the research, production, and sales of traditional Chinese medicine [1] - The main business revenue composition includes gynecological products (74.16%), urological products (17.04%), heat-clearing and detoxifying products (7.79%), and others (1.01%) [1] Stock Performance - As of September 17, the stock price of Xintian Pharmaceutical decreased by 2.06%, trading at 11.41 CNY per share, with a total market capitalization of 2.785 billion CNY [1] - Year-to-date, the stock price has increased by 21.72%, but it has seen a decline of 0.35% over the last five trading days and a 16.53% drop over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent appearance on August 20, where it recorded a net purchase of 56.32 million CNY [1] Financial Performance - For the first half of 2025, Xintian Pharmaceutical reported a revenue of 358 million CNY, a year-on-year decrease of 18.88%, and a net profit attributable to shareholders of 5.77 million CNY, down 80.99% year-on-year [2] - The company has distributed a total of 127 million CNY in dividends since its A-share listing, with 61.87 million CNY distributed over the past three years [3] Shareholder Information - As of September 10, the number of shareholders decreased to 33,700, a reduction of 5.83%, while the average circulating shares per person increased by 6.19% to 7,083 shares [2] - As of June 30, 2025, the top ten circulating shareholders included a new entry, Nuoan Multi-Strategy Mixed A, holding 1.0731 million shares, while Baodao Yuanhang Mixed A exited the top ten list [3]

Group 1 - The company, New Tian Pharmaceutical, reported that as of September 10, 2025, the number of shareholders is 33,696 [2]